Regeneron’s gene therapy for otoferlin-related hearing loss – a genetic cause of deafness – has restored hearing to normal levels in one profoundly deaf child within just
Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness
Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a
French biotech Sensorion has filed its first regulatory application to start human testing of OTOF-GT, a gene therapy for one of the most common forms of congenital deafne